Healthy adults with normal or borderline fasting blood glucose levels (<
Conditions
Interventions
None listed
Sponsors
Japan Clinical Trial Association
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants P: Healthy adults with fasting blood glucose levels in the normal or borderline range (below 126 mg/dL). Intervention I: A single oral intake of processed food containing Salacinol derived from Salacia. Limited to products based on Salacia reticulata with specified or clearly stated Salacinol content. Placebo C: A single intake of processed food not containing Salacinol derived from Salacia. Excludes products containing Salacinol or other components known to affect outcomes, unless the content is minimal and deemed not to influence the outcome. Outcome O: Suppression of postprandial blood glucose elevation. Blood glucose levels measured at 30, 60, 90, and 120 minutes after intake, and their AUC. Study Types S: Randomized controlled trials (RCTs), randomized crossover trials, quasi-randomized controlled trials, and non-RCTs. Included studies must be original articles written in English or Japanese. Short reports and articles are included only if the study content can be identified. Conference proceedings are excluded. No restrictions on the search period. Studies meeting the above criteria are grouped together without further categorization.
Exclusion criteria
Exclusion criteria: Trials that do not meet the selection criteria, such as those including patients with fasting blood glucose levels of 126 mg/dL or higher, will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postprandial blood glucose (30, 60, 90 and 120 minutes, AUC) | — |
Countries
Japan
Contacts
Public ContactTakeshi Kaneko
Japan Clinical Trial Association N/A
Outcome results
None listed